Loss of PTEN is a predictive biomarker of trastuzumab resistance in HER2 overexpressed oesophago-gastric adenocarcinoma
| Project/Area Number |
24591940
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
HIROSHI Okabe 京都大学, 医学(系)研究科(研究院), その他 (10335250)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
小濱 和貴 京都大学, 医学(系)研究科(研究院), その他 (50322649)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 胃癌 / 化学療法 / トラスツズマブ / HER2 / 分子標的治療 / EGFR / PI3K |
|---|
| Outline of Final Research Achievements |
Although previous clinical study showed significant effect of trastuzumab for HER2 overexpressed advanced oesophago-gastric adenocarcinoma, the response rate was less than 50%. This study aimed to identify a predictive biomarker of trastuzumab resistance.
In our study, PTEN loss is relatively frequent in HER2 overexpressed gastric cancer patients. PTEN loss might be a potential biomarker to select the HER2 overexpressed oesophago-gastric cancer patients who are less sensitive to the trastuzumab-based chemotherapy.
|
Report
(4 results)
Research Products
(4 results)
